Search

Rhythm Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

114.92 -0.15

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

112.33

Max

117.06

Belangrijke statistieken

By Trading Economics

Inkomsten

-49M

-105M

Verkoop

11M

71M

EPS

-0.73

Winstmarge

-147.27

Werknemers

414

EBITDA

5.9M

-44M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+22.8% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

901M

8B

Vorige openingsprijs

115.07

Vorige sluitingsprijs

114.92

Nieuwssentiment

By Acuity

22%

78%

56 / 340 Rangschikking in Healthcare

Rhythm Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 aug 2026, 19:51 UTC

Rhythm Pharmaceuticals is advancing amid broader market gains, supported by strong technology sector performance and high trading volume, despite no specific company news.

12 aug 2026, 19:46 UTC

Event

Rhythm Pharmaceuticals received expanded marketing authorization for IMCIVREE in the UK. Shares are trading higher since Tuesday's close, near the upper end of their one-month range.

11 aug 2026, 19:36 UTC

Social Media
News
Event

Rhythm Pharmaceuticals received expanded UK approval for IMCIVREE to treat obesity, yet shares are declining amid broader market sentiment concerns.

10 aug 2026, 19:31 UTC

Rhythm Pharmaceuticals Inc shares are lower today, retracing gains after an early drop. The stock is experiencing unusually high trading volume.

7 aug 2026, 20:06 UTC

News

RYTM higher after JPMorgan raised price target to $146.00.

6 aug 2026, 21:05 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reaching a high and remaining above the 20-day moving average. No specific news was identified.

5 aug 2026, 20:02 UTC

Event
News

Rhythm Pharmaceuticals shares rise as Citigroup, RBC, and Citizens raise price targets to $143, $155, and $160, respectively, reflecting growing confidence in the company.

4 aug 2026, 20:13 UTC

News

Rhythm Pharmaceuticals shares are trading higher in after-market hours following CEO and CFO participation in upcoming investor conferences, enhancing visibility among stakeholders.

3 aug 2026, 19:51 UTC

Rhythm Pharmaceuticals Inc shares are higher today amid unusually high trading volume, continuing the upward trend since Friday's close. No specific news was identified.

31 jul 2026, 22:56 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, despite earlier fluctuations and no specific news identified to explain the movement.

30 jul 2026, 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, continuing a downward trend since Wednesday. No specific news has been identified to explain the decline.

29 jul 2026, 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, influenced by rising oil prices amid escalating Middle East tensions, though no specific company news was identified.

28 jul 2026, 19:11 UTC

Rhythm Pharmaceuticals Inc. shares are higher today, supported by strong trading volume and positive momentum in the biotechnology sector. No specific news was identified.

27 jul 2026, 19:33 UTC

News

RYTM trades higher after JPMorgan's Overweight rating and $145 target.

24 jul 2026, 21:01 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reflecting a positive shift since Friday's close despite broader market challenges.

21 jul 2026, 14:36 UTC

News

Rhythm Pharmaceuticals will report second-quarter 2026 results on August 4, contributing to higher shares amid positive market sentiment and gains in the Nasdaq 100 Index.

20 jul 2026, 20:51 UTC

Rhythm Pharmaceuticals Inc is lower in after-market trading, down significantly from Monday's close and below its 20-day moving average. No specific news was identified.

Peer Vergelijking

Prijswijziging

Rhythm Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

22.8% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 142.47 USD  22.8%

Hoogste 160 USD

Laagste 105 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Rhythm Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Sentiment

By Acuity

56 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat